Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010
Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010
复制标题
DOI：
10.1111/j.1442-2042.2010.02613.x
复制
发表时间：
2010-10-01
影响因子：
2.6
通讯作者：
Ito, Kazuto
中科院分区：
文献类型：
--
作者：
Naito, Seiji;Kakehi, Yoshiyuki;Ito, Kazuto
与美国或西欧相比，日本使用前列腺特异性抗原（PSA）筛查前列腺癌的暴露率仍然很低。前列腺癌的死亡率将在未来增加，到2020年将比2000年高出2.8倍。因此，迫切需要确定降低前列腺癌死亡率的最佳对策。PSA筛查可以降低前列腺癌导致的死亡风险，应向所有有患前列腺癌风险的男性提供，并提供情况说明书，显示前列腺癌筛查的最新益处和缺点。
The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8-fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.